PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29904056-3	2018	Pyridone-containing inhibitors such as GSK126 compete with S-adenosylmethionine (SAM) for Ezh2 binding and effectively inhibit PRC2 activity.	S-Adenosylmethionine	59-79	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	90-94	
29904056-3	2018	Pyridone-containing inhibitors such as GSK126 compete with S-adenosylmethionine (SAM) for Ezh2 binding and effectively inhibit PRC2 activity.	S-Adenosylmethionine	81-84	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	90-94	
27648357-3	2016	A major class of EZH2 inhibitors are S-adenosyl-L-methionine (SAM)-competitive inhibitors, such as EPZ005687, EI1, GSK126, UNC1999 and GSK343.	S-Adenosylmethionine	37-60	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	17-21	
27648357-3	2016	A major class of EZH2 inhibitors are S-adenosyl-L-methionine (SAM)-competitive inhibitors, such as EPZ005687, EI1, GSK126, UNC1999 and GSK343.	S-Adenosylmethionine	62-65	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	17-21	
24563539-3	2014	We have previously reported the discovery of EPZ005678 and EPZ-6438, potent and selective S-adenosyl-methionine-competitive small molecule inhibitors of EZH2.	S-Adenosylmethionine	90-111	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	153-157	
26973856-3	2016	Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC.	S-Adenosylmethionine	52-75	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	107-111	
26973856-3	2016	Our previous study has demonstrated that GSK343, an S-adenosyl-L-methionine (SAM)-competitive inhibitor of EZH2, induces autophagy and enhances drug sensitivity in cancer cells including HCC.	S-Adenosylmethionine	77-80	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	107-111	
25979827-2	2015	Met is the obligate precursor of S-adenosylmethionine (SAM), the methyl donor utilized by all methyltransferases including the polycomb repressor complex (PRC2)-specific EZH2.	S-Adenosylmethionine	33-53	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	170-174	
25979827-2	2015	Met is the obligate precursor of S-adenosylmethionine (SAM), the methyl donor utilized by all methyltransferases including the polycomb repressor complex (PRC2)-specific EZH2.	S-Adenosylmethionine	55-58	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	170-174	
25203626-0	2015	S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.	S-Adenosylmethionine	0-23	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	80-84	
24767850-6	2014	Based on enzyme kinetics and docking studies, we propose that tanshindiol-mediated inhibition of EZH2 activity is competitive for the substrate S-adenosylmethionine.	S-Adenosylmethionine	146-164	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	97-101	
23236167-3	2012	To investigate if tumor growth is dependent on the enzymatic activity of Ezh2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine.	S-Adenosylmethionine	271-292	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	73-77	
23236167-3	2012	To investigate if tumor growth is dependent on the enzymatic activity of Ezh2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine.	S-Adenosylmethionine	271-292	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	187-191